Fisher, Matthew C. http://orcid.org/0000-0002-1862-6402
Alastruey-Izquierdo, Ana http://orcid.org/0000-0001-8651-4405
Berman, Judith http://orcid.org/0000-0002-8577-0084
Bicanic, Tihana http://orcid.org/0000-0002-2676-838X
Bignell, Elaine M. http://orcid.org/0000-0001-7748-1920
Bowyer, Paul
Bromley, Michael http://orcid.org/0000-0002-7611-0201
Brüggemann, Roger
Garber, Gary
Cornely, Oliver A. http://orcid.org/0000-0001-9599-3137
Gurr, Sarah. J. http://orcid.org/0000-0002-4821-0635
Harrison, Thomas S.
Kuijper, Ed
Rhodes, Johanna http://orcid.org/0000-0002-1338-7860
Sheppard, Donald C. http://orcid.org/0000-0001-8877-880X
Warris, Adilia http://orcid.org/0000-0001-6586-3358
White, P. Lewis http://orcid.org/0000-0003-3056-4205
Xu, Jianping http://orcid.org/0000-0003-2915-2780
Zwaan, Bas http://orcid.org/0000-0002-8221-4998
Verweij, Paul E. http://orcid.org/0000-0002-8600-9860
Article History
Accepted: 1 March 2022
First Online: 29 March 2022
Competing interests
: M.C.F. and P.E.V. receive speaker fees from Gilead Scientific. O.A.C. reports grants or contracts from Amplyx, Basilea, BMBF, Cidara, DZIF, EU-DG RTD (101037867), F2G Ltd, Gilead, Matinas, MedPace, MSD, Mundipharma, Octapharma, Pfizer and Scynexis; consulting fees from Amplyx, Biocon, Biosys, Cidara, Da Volterra, Gilead, Matinas, MedPace, Menarini, Molecular Partners, MSG-ERC, Noxxon, Octapharma, PSI, Scynexis and Seres; honoraria for lectures from Abbott, Al-Jazeera Pharmaceuticals, Astellas, Grupo Biotoscana/United Medical/Knight, Hikma, MedScape, MedUpdate, Merck/MSD, Mylan and Pfizer; payment for expert testimony from Cidara; participation on a Data Safety Monitoring Board or Advisory Board from Actelion, Allecra, Cidara, Entasis, IQVIA, Jannsen, MedPace, Paratek, PSI and Shionogi; a patent at the German Patent and Trade Mark Office (DE 10 2021 113 007.7); and other interests from DGHO, DGI, ECMM), ISHAM, MSG-ERC and Wiley. The other authors declare no competing interests.
Free to read: This content has been made available to all.